Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected east africans (RV 172)
Journal of Infectious Diseases, Volume 201, No. 4, Year 2010
Notification
URL copied to clipboard!
Description
Background. Human immunodeficiency virus (HIV) vaccine development remains a global priority. We describe the safety and immunogenicity of a multiclade DNA vaccine prime with a replication-defective recombinant adenovirus serotype 5 (rAd5) boost. Methods. The vaccine is a 6-plasmid mixture encoding HIV envelope (env) subtypes A, B, and C and subtype B gag, pol, and nef, and an rAd5 expressing identical genes, with the exception of nef. Three hundred and twentyfour participants were randomized to receive placebo (n = 138), a single dose of rAd5 at 10 10 (n = 24) or 10 11 particle units (n = 24), or DNA at 0, 1, and 2 months, followed by rAd5 at either 10 10 (n = 114) or 10 11 particle units (n = 24) boosting at 6 months. Participants were followed up for 24 weeks after the final vaccination. Results. The vaccine was safe and well tolerated. HIV-specific T cell responses were detected in 63% of vaccinees. Titers of preexisting Ad5 neutralizing antibody did not affect the frequency and magnitude of T cell responses in prime-boost recipients but did affect the response rates in participants that received rAd5 alone (P = .037). Conclusion. The DNA/rAd5 vaccination regimen was safe and induced HIV type 1 multi-clade T cell responses, which were not significantly affected by titers of preexisting rAd5 neutralizing antibody. © 2010 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
Kibuuka, Hannah N.
Uganda, Kampala
Makerere University
Kimutai, Robert L.
Kenya, Nairobi
Us Army Medical Research Unit-kenya
Maboko, Leonard L.
Tanzania
Mbeya Medical Research Programme
Sawe, Fredrick Kipyego
Kenya, Nairobi
Us Army Medical Research Unit-kenya
Schunk, Mirjam S.
Tanzania
Mbeya Medical Research Programme
Germany, Munich
Klinikum Der Universität München
Kroidl, Arne L.
Tanzania
Mbeya Medical Research Programme
Germany, Munich
Klinikum Der Universität München
Shaffer, Douglas N.
Kenya, Nairobi
Us Army Medical Research Unit-kenya
Eller, Leigh Anne
Uganda, Kampala
Makerere University
United States, Silver Spring
Us Military Hiv Research Program
Kibaya, Rukia M.
Kenya, Nairobi
Us Army Medical Research Unit-kenya
Eller, Michael A.
Uganda, Kampala
Makerere University
United States, Silver Spring
Us Military Hiv Research Program
Schindler, Karin B.
Tanzania
Mbeya Medical Research Programme
Germany, Munich
Klinikum Der Universität München
Schuetz, Alexandra
Tanzania
Mbeya Medical Research Programme
Germany, Munich
Klinikum Der Universität München
Millard, Monica
Uganda, Kampala
Makerere University
Kroll, Jason
United States, Rockville
The Emmes Corporation
Dally, Len G.
United States, Rockville
The Emmes Corporation
Höelscher, Michael
Tanzania
Mbeya Medical Research Programme
Germany, Munich
Klinikum Der Universität München
Bailer, Robert T.
United States, Bethesda
National Institute of Allergy and Infectious Diseases Niaid
Cox, Josephine H.
United States, New York
International Aids Vaccine Initiative
Marovich, Mary Anne
United States, Silver Spring
Us Military Hiv Research Program
Birx, Deborah L.
United States, Atlanta
Centers for Disease Control and Prevention
Graham, Barney S.
United States, Bethesda
National Institute of Allergy and Infectious Diseases Niaid
Michael, Nelson L.
United States, Silver Spring
Us Military Hiv Research Program
de Souza, Mark S.
United States, Silver Spring
Us Military Hiv Research Program
Thailand, Bangkok
Armed Forces Research Institute of Medical Sciences, Thailand
Robb, Merlin Lee
United States, Silver Spring
Us Military Hiv Research Program
Statistics
Citations: 118
Authors: 24
Affiliations: 10
Identifiers
Doi:
10.1086/650299
ISSN:
00221899
Research Areas
Genetics And Genomics
Infectious Diseases